Multicancer Early Detection Screening Improves Patient Outcomes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 9, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 9, 2025 -- Annual multicancer early detection (MCED) screening with a single blood test provides more overall benefit than biennial MCED screening, according to a study published online May 8 in BMJ Open.

Brian Rous, M.B., B.Chir., Ph.D., from Cambridge University in the United Kingdom, and colleagues estimated the effect of screening with an MCED test at different intervals (emphasis on annual and biennial screening) on cancer stage at diagnosis and mortality end points. Two sets of tumor growth scenarios were investigated: fast (two to four years in stage I) and fast aggressive (one to two years in stage I). The inputs for the current model were published MCED performance measures from a large case-control study and Surveillance, Epidemiology and End Results data for persons aged 50 to 79 years for all cancer incidence.

The researchers found that under the fast tumor growth scenario, annual screening was associated with more favorable diagnostic yield. Compared with usual care, there were 370 more cancer signals detected/year/100,000 people screened, 49 percent fewer late-stage diagnoses, and 21 percent fewer deaths within five years. A similar, but less substantial, effect was seen with biennial screening compared with usual care (292 more cancer signals detected, 39 percent fewer late-stage diagnoses, and 17 percent fewer deaths within five years). For the fast tumor growth scenario, annual screening prevented more deaths within five years than the biennial scenario. However, a higher positive predictive value was seen with biennial screening (54 versus 43 percent); it was more efficient for preventing deaths within five years per 100,000 tests (132 versus 84) but prevented fewer deaths per year.

"The optimal choice of screening interval will depend on assessments of real-world cancer survival and the costs of confirmatory testing after MCED screening," the authors write.

Several authors disclosed ties to biotechnology companies, including GRAIL, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-10 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords